ROCHE DIAGNOSTICS LIMITED
Location
Founded
1956-09-14
Website
Risk Signals
24759 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ROCHE DIAGNOSTICS LIMITED
Live alerts from global media, monitored by Business Radar
2025-07-10 (koreabiomed.com)
Korean health agency recognizes HER2 companion diagnostic tests as Level 2 reimbursement target < Policy < Article -
The Health Insurance Review and Assessment Service (HIRA) has officially determined that the "Level 2" companion diagnosis reimbursement is appropriate for the HER2 (Human Epidermal growth factor Receptor 2) companion diagnostic immunohistochemical (IHC) test, which has been a key concern for pathol
Read more
2025-05-26 (remedium.ru)
EMA approved a new scheme for the use of Alea from Bayer |
The drug gained an advantage over its competitor to Vabismo from Roche. According to the new recommendations of EMA, in the treatment of moist form of age -related maculodistrophy and diabetic macular edema, the drug should be administered in a high dose of 8 mg with an interval of up to six months.
Read more
2025-03-12 (24-horas.mx)
Duo Effaclar Cream is withdrawn from US by risk of carcinogenic chemist
The FDA of the US ordered the urgent withdrawal of the market The Effaclar Duo facial cream due to the risk of carcinogenic chemical.
Read more
2023-09-29 (fiercepharma.com)
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
After establishing Venclexta as a treatment for chronic lymphocytic leukemia( CLL) and acute myeloid leukemia( AML), AbbVie and Roche were hoping to demonstrate the med 's promise in a subset of mul| Despite the trial missing its primary endpoint of progression-free survival, the companies will soon
Read more
2023-08-30 (fiercepharma.com)
FDA turns down Outlook's ophthalmic version of Roche's Avastin over manufacturing, data shortfalls
Even without an FDA approval, Roche's cancer drug Avastin is widely used by doctors to treat certain eye diseases.
Read more
(fiercepharma.com)
FDA lets Endo, Dr. Reddy's make Valcyte copies but stays mum on status of Nexium generic |
The FDA says it has approved two companies to make generics of Roche's Valcyte but will not give any clarity on plans for a generic of AstraZeneca's blockbuster Nexium after nixing earlier approvals for troubled Ranbaxy Laboratories to make both drugs. | The FDA says it has approved two companies to make generics of Roche's Valcyte but will not give any clarity on plans for a generic of AstraZeneca's blockbuster Nexium after nixing earlier approvals for troubled Ranbaxy Laboratories to make both drugs.
Read more